Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls

Akçay İ. M. , Celik E., Agaoglu N. B. , Alkurt G., Akgun T. K. , Yildiz J., ...More

INTERNATIONAL JOURNAL OF CANCER, vol.148, no.2, pp.285-295, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 148 Issue: 2
  • Publication Date: 2021
  • Doi Number: 10.1002/ijc.33199
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, Food Science & Technology Abstracts, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.285-295
  • Istanbul Technical University Affiliated: Yes


Inherited pathogenic variants account for 5% to 10% of all breast cancer (BC) and colorectal cancer (CRC) cases. Here, we sought to profile the pathogenic variants in 25 cancer susceptibility genes in Turkish population. Germline pathogenic variants were screened in 732 BC patients, 189 CRC patients and 490 cancer-free elderly controls, using next-generation sequencing-based multigene panel testing and multiplex ligation-dependent probe amplification testing. Pathogenic variants were detected in 17.2% of high-risk BC patients and 26.4% of high-risk CRC patients. More than 95% of these variants were clinically actionable.BRCA1/2and mismatch repair genes (MLH1,MSH2andMSH6) accounted for two-thirds of all pathogenic variants detected in high-risk BC and CRC patients, respectively. Pathogenic variants inPALB2,CHEK2,ATMandTP53were also prevalent in high-risk BC patients (4.5%).BRCA1exons 17-18 deletion andCHEK2c.592+3A>T were the most common variants predisposing to BC, and they are likely to be founder variants. Three frequentMUTYHpathogenic variants (c.884C>T, c.1437_1439delGGA and c.1187G>A) were responsible for allMUTYHbiallelic cases (4.4% of high-risk CRC patients). The total pathogenic variant frequency was very low in controls (2.4%) and in low-risk BC (3.9%) and CRC (6.1%) patients. Our study depicts the pathogenic variant spectrum and prevalence in Turkish BC and CRC patients, guiding clinicians and health authorities for genetic testing applications and variant classification in Turkish population.